New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
11:15 EDTJNJJanssen enters license and R&D agreements with GlycoVaxyn AG
GlycoVaxyn AG announced that Janssen Pharmaceuticals, Inc. has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. GlycoVaxyn will collaborate with JPI's affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which JPI will be responsible for later-stage clinical studies and world-wide commercialization. The consideration to GlycoVaxyn includes an upfront payment, milestone payments, royalties as well as reimbursement of research and development expenses. Financial details of the agreement have not been disclosed. Janssen Pharmaceuticals is a pharmaceutical company of Johnson & Johnson.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:35 EDTJNJNewYorkBio to hold a conference
Subscribe for More Information
May 3, 2015
18:11 EDTJNJSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
07:43 EDTJNJExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 29, 2015
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
April 27, 2015
06:19 EDTJNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
April 20, 2015
14:32 EDTJNJPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
06:59 EDTJNJJohnson & Johnson added to short-term buy list at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use